517 related articles for article (PubMed ID: 34160093)
1. Recent advances in antibody-based immunotherapy strategies for COVID-19.
Esmaeilzadeh A; Rostami S; Yeganeh PM; Tahmasebi S; Ahmadi M
J Cell Biochem; 2021 Oct; 122(10):1389-1412. PubMed ID: 34160093
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
[TBL] [Abstract][Full Text] [Related]
3. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.
Tabll AA; Shahein YE; Omran MM; Elnakib MM; Ragheb AA; Amer KE
Hum Antibodies; 2021; 29(3):179-191. PubMed ID: 33998533
[TBL] [Abstract][Full Text] [Related]
4. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
6. Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects.
Sharun K; Tiwari R; Iqbal Yatoo M; Patel SK; Natesan S; Dhama J; Malik YS; Harapan H; Singh RK; Dhama K
Expert Opin Biol Ther; 2020 Sep; 20(9):1033-1046. PubMed ID: 32744917
[TBL] [Abstract][Full Text] [Related]
7. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.
Liu X; Cao W; Li T
Front Immunol; 2020; 11():1660. PubMed ID: 32760407
[TBL] [Abstract][Full Text] [Related]
8. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
9. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.
Chen J; Huang R; Nie Y; Wen X; Wu Y
Virol Sin; 2020 Dec; 35(6):713-724. PubMed ID: 33394351
[TBL] [Abstract][Full Text] [Related]
10. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.
Strohl WR; Ku Z; An Z; Carroll SF; Keyt BA; Strohl LM
BioDrugs; 2022 May; 36(3):231-323. PubMed ID: 35476216
[TBL] [Abstract][Full Text] [Related]
11. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.
Hwang YC; Lu RM; Su SC; Chiang PY; Ko SH; Ke FY; Liang KH; Hsieh TY; Wu HC
J Biomed Sci; 2022 Jan; 29(1):1. PubMed ID: 34983527
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
14. Potential therapeutic options for COVID-19: an update on current evidence.
Niknam Z; Jafari A; Golchin A; Danesh Pouya F; Nemati M; Rezaei-Tavirani M; Rasmi Y
Eur J Med Res; 2022 Jan; 27(1):6. PubMed ID: 35027080
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview.
Ali MG; Zhang Z; Gao Q; Pan M; Rowan EG; Zhang J
Immunol Res; 2020 Dec; 68(6):325-339. PubMed ID: 33161557
[TBL] [Abstract][Full Text] [Related]
16. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.
Valdez-Cruz NA; García-Hernández E; Espitia C; Cobos-Marín L; Altamirano C; Bando-Campos CG; Cofas-Vargas LF; Coronado-Aceves EW; González-Hernández RA; Hernández-Peralta P; Juárez-López D; Ortega-Portilla PA; Restrepo-Pineda S; Zelada-Cordero P; Trujillo-Roldán MA
Microb Cell Fact; 2021 Apr; 20(1):88. PubMed ID: 33888152
[TBL] [Abstract][Full Text] [Related]
17. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing monoclonal antibodies for treatment of COVID-19.
Taylor PC; Adams AC; Hufford MM; de la Torre I; Winthrop K; Gottlieb RL
Nat Rev Immunol; 2021 Jun; 21(6):382-393. PubMed ID: 33875867
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
Jiang S; Hillyer C; Du L
Trends Immunol; 2020 May; 41(5):355-359. PubMed ID: 32249063
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody therapies against SARS-CoV-2.
Focosi D; McConnell S; Casadevall A; Cappello E; Valdiserra G; Tuccori M
Lancet Infect Dis; 2022 Nov; 22(11):e311-e326. PubMed ID: 35803289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
